TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Brief Summary: The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.


Options:
A: Arm Label: Vadadustat once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat three times weekly (TIW); Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat once daily (QD), Vadadustat three times weekly (TIW) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: Daprodustat receivers; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat (GSK1278863), Drug: Iron therapy | Arm Label: Placebo receivers; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat (GSK1278863); Assigned to Arm(s): Daprodustat receivers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo receivers | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat receivers, Placebo receivers
C: Arm Label: ASP1517 Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin alfa Group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 Group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa Group
D: Arm Label: Molidustat group; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo of Darbepoetin alfa | Arm Label: Darbepoetin alfa group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Placebo of Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Molidustat (BAY85-3934); Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Darbepoetin alfa; Assigned to Arm(s): Molidustat group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Community-based Assessment of Skin Care, Allergies, and Eczema
Brief Summary: Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders. Recent advances identify skin barrier dysfunction to be the key initiator of AD and possibly allergic sensitization.

Our central hypothesis is that daily emollient use from birth can prevent the development of AD in a community setting and into newborns unselected for risk. The results of a community-based clinical trial utilizing a pragmatic trial design will be immediately applicable to the population at large and will establish a new standard of care for all newborns.


Options:
A: Arm Label: Domestic ion-exchange water softener; Type: EXPERIMENTAL; Interventions: Device: Domestic ion-exchange water softener | Arm Label: Usual hard water supply; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Domestic ion-exchange water softener; Assigned to Arm(s): Domestic ion-exchange water softener
B: Arm Label: Observation only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food intervention; Type: EXPERIMENTAL; Interventions: Other: Food intervention | Arm Label: Skin care; Type: EXPERIMENTAL; Interventions: Other: Skin care | Arm Label: Food intervention and skin care; Type: EXPERIMENTAL; Interventions: Other: Food intervention, Other: Skin care | Intervention Type: OTHER; Name: Food intervention; Assigned to Arm(s): Food intervention, Food intervention and skin care | Intervention Type: OTHER; Name: Skin care; Assigned to Arm(s): Food intervention and skin care, Skin care
C: Arm Label: Twice daily use treatment with EpiCeram; Type: ACTIVE_COMPARATOR; Interventions: Drug: EpiCeram | Arm Label: Standard skin care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EpiCeram; Assigned to Arm(s): Twice daily use treatment with EpiCeram
D: Arm Label: Daily Emollient; Type: EXPERIMENTAL; Interventions: Other: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream | Arm Label: Natural Skin; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Assigned to Arm(s): Daily Emollient

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Community-based Assessment of Skin Care, Allergies, and Eczema
Brief Summary: Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders. Recent advances identify skin barrier dysfunction to be the key initiator of AD and possibly allergic sensitization.

Our central hypothesis is that daily emollient use from birth can prevent the development of AD in a community setting and into newborns unselected for risk. The results of a community-based clinical trial utilizing a pragmatic trial design will be immediately applicable to the population at large and will establish a new standard of care for all newborns.


Options:
A: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
B: Arm Label: Daily Emollient; Type: EXPERIMENTAL; Interventions: Other: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream | Arm Label: Natural Skin; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Assigned to Arm(s): Daily Emollient
C: Arm Label: Topical Emollient; Type: EXPERIMENTAL; Interventions: Other: Topical Emollient | Arm Label: Routine Skin Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Topical Emollient; Assigned to Arm(s): Topical Emollient
D: Arm Label: Domestic ion-exchange water softener; Type: EXPERIMENTAL; Interventions: Device: Domestic ion-exchange water softener | Arm Label: Usual hard water supply; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Domestic ion-exchange water softener; Assigned to Arm(s): Domestic ion-exchange water softener

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Brief Summary: Despite improvements and advances in pancreas surgery, about 30-35% of patients who have pancreas surgery develop a type of complication called a pancreatic fistula. A pancreatic fistula occurs when fluid produced by the pancreas leaks into the abdomen after pancreas surgery. Patients who develop a pancreatic fistula can have poor short-term and long-term consequences.We are studying the effect of a medical device named HEMOPATCH on the development and seriousness of pancreatic fistulas. HEMOPATCH is a thin, flexible bovine protein-based pad that may improve tissue sealing where it is applied during surgery. Some small studies called case studies of between 2 and 7 patients, and two clinical trials have shown that HEMOPATCH is effective at stopping bleeding and reducing drain output after some types of surgery. However, there have been no completed clinical trials using HEMOPATCH to prevent or reduce pancreatic fistulas in patients having pancreas surgery, so we don't know if it works in this setting. Health Canada has approved the use of HEMOPATCH as a device to stop bleeding or seal other bodily fluids for procedures in which the control of bleeding or leakage of other body fluids or air by standard surgical techniques are either ineffective or impractical.


Options:
A: Arm Label: Patch and glue arm; Type: EXPERIMENTAL; Interventions: Procedure: Falciform patch and fibrin glue application | Arm Label: stapled /sutured pancreatic closure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard pancreatic closure | Intervention Type: PROCEDURE; Name: Falciform patch and fibrin glue application; Assigned to Arm(s): Patch and glue arm | Intervention Type: PROCEDURE; Name: standard pancreatic closure; Assigned to Arm(s): stapled /sutured pancreatic closure
B: Arm Label: Tachocomb; Type: ACTIVE_COMPARATOR; Interventions: Device: Tachocomb | Arm Label: PGA; Type: ACTIVE_COMPARATOR; Interventions: Device: Polyglycolic acid (PGA) (Neoveil) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tachocomb; Assigned to Arm(s): Tachocomb | Intervention Type: DEVICE; Name: Polyglycolic acid (PGA) (Neoveil); Assigned to Arm(s): PGA
C: Arm Label: Pancreatic duct occlusion; Type: EXPERIMENTAL; Interventions: Procedure: Pancreatic duct occlusion with Neoprene | Arm Label: Pancreato-Jejunal anastomosi; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pancreato-Jejunal anastomosis | Intervention Type: PROCEDURE; Name: Pancreatic duct occlusion with Neoprene; Assigned to Arm(s): Pancreatic duct occlusion | Intervention Type: PROCEDURE; Name: Pancreato-Jejunal anastomosis; Assigned to Arm(s): Pancreato-Jejunal anastomosi
D: Arm Label: Hemopatch; Type: EXPERIMENTAL; Interventions: Device: Hemopatch | Intervention Type: DEVICE; Name: Hemopatch; Assigned to Arm(s): Hemopatch

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab Escape arm; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab Escape arm, Bimekizumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab cohort, Placebo
B: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab Escape arm; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab Escape arm, Bimekizumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab cohort, Placebo
D: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeting Balance Confidence as a Strategy to Increase Integration and Improve Outcomes in Users of Lower-Limb Prostheses
Brief Summary: Low balance confidence occurs when an individual perceives they have limited ability to maintain their balance while performing a specific task of daily living. It is a prevalent problem in lower limb prosthesis users and is a strong predictor of prosthesis use and community participation. Balance confidence is not necessarily related to functional abilities. It is possible to improve functional ability as a result of rehabilitation, without concurrently improving balance confidence. Interventions to address low balance confidence may need to target both functional abilities as well as beliefs regarding these abilities. The purpose of this study is to test whether, for users of lower limb prostheses, an intervention combining physical therapy exercise to improve function with cognitive behavioral therapy to address fears and thoughts associated with low confidence can improve balance confidence and promote community participation.


Options:
A: Arm Label: Exercise Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly exercise sessions with physical therapist and psychologist | Arm Label: Exercise Group B; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Home-based exercises | Intervention Type: BEHAVIORAL; Name: Weekly exercise sessions with physical therapist and psychologist; Assigned to Arm(s): Exercise Group A | Intervention Type: BEHAVIORAL; Name: Home-based exercises; Assigned to Arm(s): Exercise Group B
B: Arm Label: Exercise, activity, and self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Walking Program, Behavioral: Health Self-Management Support | Arm Label: Home and phone visit; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Walking Program; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Health Self-Management Support; Assigned to Arm(s): Exercise, activity, and self-management
C: Arm Label: SMART & Peer Support; Type: EXPERIMENTAL; Interventions: Device: Self-Management for Amputee Rehabilitation using Technology [SMART] | Intervention Type: DEVICE; Name: Self-Management for Amputee Rehabilitation using Technology [SMART]; Assigned to Arm(s): SMART & Peer Support
D: Arm Label: Not Meeting Mobility Goals; Type: EXPERIMENTAL; Interventions: Other: Needs-based intervention (physical, psychological, or both) | Intervention Type: OTHER; Name: Needs-based intervention (physical, psychological, or both); Assigned to Arm(s): Not Meeting Mobility Goals

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study
Brief Summary: Safety and efficacy of addition of hyaluronidase to lidocaine and bupivacaine in scalp nerves block in elective craniotomy operations,Comparative study


Options:
A: Arm Label: Group H (Hyaluronidase added to local anaesthetics); Type: ACTIVE_COMPARATOR; Interventions: Drug: Hyaluronidase, Drug: Lidocaine, Drug: Bupivacaine | Arm Label: Group A (local anaesthetics alone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine, Drug: Bupivacaine | Intervention Type: DRUG; Name: Hyaluronidase; Assigned to Arm(s): Group H (Hyaluronidase added to local anaesthetics) | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group A (local anaesthetics alone), Group H (Hyaluronidase added to local anaesthetics) | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Group A (local anaesthetics alone), Group H (Hyaluronidase added to local anaesthetics)
B: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous acetaminophen | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for IV acetaminophen | Intervention Type: DRUG; Name: Intravenous acetaminophen; Assigned to Arm(s): Intervention group | Intervention Type: DRUG; Name: Placebo for IV acetaminophen; Assigned to Arm(s): Placebo Group
C: Arm Label: Sumatriptan; Type: EXPERIMENTAL; Interventions: Drug: Sumatriptan, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sumatriptan, Other: Placebo | Intervention Type: DRUG; Name: Sumatriptan; Assigned to Arm(s): Placebo, Sumatriptan | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Sumatriptan
D: Arm Label: Lyrica; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Lyrica | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).


Options:
A: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo solution for risankizumab | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo solution for risankizumab; Assigned to Arm(s): Placebo
B: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Arm Label: Bimekizumab Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Adalimumab Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Adalimumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2

Answer: D